TLX Telix Pharmaceuticals Limited

AMX
$10.72

Telix Pharmaceuticals Limited (TLX) is expected to report earnings on August 19, 2026, after the market close. The consensus earnings estimate is a loss of $0.04 per share.

Earnings Date
3rd Quarter, Sep 2026
Aug 19
Wednesday · 5:50 PM ET
Earnings Whisper
-
vs ($0.04)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Th company is developing a portfolio of clinical and commercial stage products which aims to address significant unmet medical needs in oncology and rare diseases. Telix Pharmaceuticals Limited, formerly known as TLX PHARMACEUT, is based in MELBOURNE, Australia.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.